Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
HT-100
Processa Pharmaceuticals
Duchenne Muscular Dystrophy
2 trials -
PCS12852
Processa Pharmaceuticals
Gastroparesis
1 trial -
PCS499
Processa Pharmaceuticals
Necrobiosis Lipoidica
2 trials -
PCS6422 and capecitabine
Processa Pharmaceuticals
Breast Cancer
1 trial -
RX-3117
Processa Pharmaceuticals
Solid Tumor
1 trial -
RX-3117
Processa Pharmaceuticals
Metastatic Pancreatic Cancer
1 trial -
PCS499
Processa Pharmaceuticals
Healthy
1 trial -
PCS6422 and capecitabine
Processa Pharmaceuticals
Advanced Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources